Skip to main content

Advertisement

SpringerLink
Log in

Correlation of FANCM expression with clinical factors in luminal B breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

The genotype of Fanconi Anemia complementation group M (FANCM) was previously found to be associated with breast cancer risk in several populations. Here, we studied the expression of FANCM and its correlation with clinical characteristics in Chinese patients with breast cancer.

Methods

We performed an immunohistochemical study of FANCM protein in clinical breast cancer tissues from 310 patients along with 44 adjacent tissues.

Results

FANCM protein level is lower in triple-negative breast cancer tissues than in other subtypes (P = 0.008). In addition, high FANCM expression correlated with pathology type IDC (P = 0.040), estrogen receptor positive (P < 0.001), progesterone receptor positive (P = 0.001), and low Ki-67 status (P = 0.003). Multivariate analysis revealed that FANCM status was an independent prognostic factor for overall survival (P = 0.017) in luminal B breast cancer.

Conclusions

FANCM levels are significantly associated with different subtypes of human breast cancer. Specifically, FANCM could play a role in the progression of luminal B breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Miller K, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    Article  PubMed  Google Scholar 

  2. Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China. CA Cancer J Clin. 2015;66(2):115–32.

    Article  CAS  Google Scholar 

  3. Heilmann K. Epigenetic characterization of the C3(1) SV40T mouse model of human breast cancer. 2017.

  4. Holm J, Eriksson L, Ploner A, Eriksson M, Rantalainen M, Li J, et al. Assessment of breast cancer risk factors reveals subtype heterogeneity. Cancer Res. 2017;77(13):3708–17.

    Article  PubMed  CAS  Google Scholar 

  5. Martín-Sánchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Córdoba A, Vicente-García F, et al. CDH22hypermethylation is an independent prognostic biomarker in breast cancer. Clin Epigenetics. 2017;9(1):7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Ling C, Huang J, Yan Z, Li Y, Ohzeki M, Ishiai M, et al. Bloom syndrome complex promotes FANCM recruitment to stalled replication forks and facilitates both repair and traverse of DNA interstrand crosslinks. Cell Discov. 2016;2:16047.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Ali AM, Singh TR, Meetei AR. FANCM-FAAP24 and FANCJ: FA proteins that metabolize DNA. Mutat Res. 2009;668(1–2):20–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Xue X, Sung P, Zhao X. Functions and regulation of the multitasking FANCM family of DNA motor proteins. Genes Dev. 2015;29(17):1777–88.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Rohleder F, Huang J, Xue Y, Kuper J, Round A, Seidman M, et al. FANCM interacts with PCNA to promote replication traverse of DNA interstrand crosslinks. Nucl Acids Res. 2016;44(7):3219–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, et al. Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget. 2017;8(31):50930–40.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Neidhardt G, Hauke J, Ramser J, Gross E, Gehrig A, Muller CR, et al. Association between loss-of-function mutations within the FANCM gene and early-onset familial breast cancer. JAMA Oncol. 2017;3(9):1245–8.

    Article  PubMed  Google Scholar 

  12. Catucci I, Osorio A, Arver B, Neidhardt G, Bogliolo M, Zanardi F, et al. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genet Med. 2017. https://doi.org/10.1038/gim.2017.123.

    Article  PubMed  Google Scholar 

  13. Kiiski JI, Fagerholm R, Tervasmaki A, Pelttari LM, Khan S, Jamshidi M, et al. FANCM c.5101C > T mutation associates with breast cancer survival and treatment outcome. Int J Cancer. 2016;139(12):2760–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

    Article  PubMed  Google Scholar 

  16. Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, et al. FANCM c.5791C > T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Hum Mol Genet. 2015;24(18):5345–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Rashid MU, Muhammad N, Khan FA, Hamann U. Absence of the FANCM c.5101C > T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan. Breast Cancer Res Treat. 2015;152(1):229–30.

    Article  PubMed  Google Scholar 

  18. Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci USA. 2014;111(42):15172–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Kiiski JI, Tervasmaki A, Pelttari LM, Khan S, Mantere T, Pylkas K, et al. FANCM mutation c.5791C > T is a risk factor for triple-negative breast cancer in the Finnish population. Breast Cancer Res Treat. 2017;66(1):217–26.

    Article  CAS  Google Scholar 

  20. Pan X, Drosopoulos WC, Sethi L, Madireddy A, Schildkraut CL, Zhang D. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. Proc Natl Acad Sci USA. 2017;114(29):E5940–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Krammer J, Pinker-Domenig K, Robson ME, Gonen M, Bernard-Davila B, Morris EA, et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2017;163(3):565–71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80.

    Article  PubMed  CAS  Google Scholar 

  23. Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, et al. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017;17(1):124.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat. 2017;161(1):173–9.

    Article  PubMed  Google Scholar 

  25. Cheang MCU, Chia SK, Voduc D, Gao DX, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363–71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Berton S, Cusan M, Segatto I, Citron F, D’Andrea S, Benevol S, et al. Loss of p27 kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Sci Rep. 2017;7(1):595.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Schwab RA, Blackford AN, Niedzwiedz W. ATR activation and replication fork restart are defective in FANCM-deficient cells. EMBO J. 2010;29(4):806–18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (81572591).

Author information

Author notes

  1. Yiran Wang, Junnan Wang and Fei Long contributed equally to this work.

Authors and Affiliations

  1. Department of Oncology, Changhai Hospital, Second Military Medical University, Shanghai, China

    Yiran Wang, Fei Long, Ning Wang & Yajie Wang

  2. Cadet Brigade, Second Military Medical University, Shanghai, China

    Junnan Wang

  3. Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, China

    Bingbing Zhang & Huan Han

Authors
  1. Yiran Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junnan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fei Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ning Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bingbing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huan Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yajie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yajie Wang.

Ethics declarations

Conflict of interest

The authors have declared no conflicts of interest.

Ethical approval

Ethical approval is in accordance with the Declaration of Helsinki.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Wang, J., Long, F. et al. Correlation of FANCM expression with clinical factors in luminal B breast cancer. Breast Cancer 25, 431–437 (2018). https://doi.org/10.1007/s12282-018-0841-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-018-0841-0

Keywords

Search

Navigation